Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis
British Journal of Clinical Pharmacology2013Vol. 76(3), pp. 348–357
Citations Over TimeTop 1% of 2013 papers
Abstract
While sharing a similar spectrum of target receptors with other VEGFR-TKIs, axitinib is associated with an unexpectedly high risk of developing hypertension. Close monitoring and appropriate management for hypertension are recommended during the treatment.
Related Papers
- → Concise Drug Review: Pazopanib and Axitinib(2012)84 cited
- → Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment(2016)1 cited
- → Axitinib in advanced renal cell carcinoma: Outcomes following pazopanib or sunitinib.(2016)1 cited
- → Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib(2017)
- → Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome.(2017)